Live thread

Akeso ivonescimab shows survival benefit in lung cancer — ASCO 2026 trial results

At the ASCO26 cancer conference, Chinese biotech company Akeso presented study results demonstrating a significant survival benefit for its immunotherapy drug ivonescimab in lung cancer. Patients who received the drug lived an average of four months longer.

This story is part of Kirla. Sign in to read the full coverage.

Sign in to read